251 related articles for article (PubMed ID: 27334838)
1. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer.
Ikeda Y; Park JH; Miyamoto T; Takamatsu N; Kato T; Iwasa A; Okabe S; Imai Y; Fujiwara K; Nakamura Y; Hasegawa K
Clin Cancer Res; 2016 Dec; 22(24):6110-6117. PubMed ID: 27334838
[TBL] [Abstract][Full Text] [Related]
2. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Stefka AT; Johnson D; Rosebeck S; Park JH; Nakamura Y; Jakubowiak AJ
Cancer Med; 2020 Jan; 9(1):324-334. PubMed ID: 31714026
[TBL] [Abstract][Full Text] [Related]
3. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
4. T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cell Prolif; 2020 Oct; 53(10):e12901. PubMed ID: 32960500
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
7. [
Pirovano G; Roberts S; Brand C; Donabedian PL; Mason C; de Souza PD; Higgins GS; Reiner T
Mol Imaging Biol; 2019 Aug; 21(4):705-712. PubMed ID: 30357568
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription.
Wang Y; Yun Y; Wu B; Wen L; Wen M; Yang H; Zhao L; Liu W; Huang S; Wen N; Li Y
Oncotarget; 2016 Jul; 7(30):47985-47997. PubMed ID: 27351131
[TBL] [Abstract][Full Text] [Related]
9. T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.
Thanindratarn P; Wei R; Dean DC; Singh A; Federman N; Nelson SD; Hornicek FJ; Duan Z
Mol Oncol; 2021 Dec; 15(12):3721-3737. PubMed ID: 34115928
[TBL] [Abstract][Full Text] [Related]
10. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.
Herbert KJ; Ashton TM; Prevo R; Pirovano G; Higgins GS
Cell Death Dis; 2018 Oct; 9(11):1089. PubMed ID: 30356039
[TBL] [Abstract][Full Text] [Related]
11. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
15. Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma.
Hayashi T; Hayakawa Y; Koh M; Tomita T; Nagai S; Kashiwazaki D; Sugimori M; Origasa H; Kuroda S
Neuropathology; 2018 Apr; 38(2):144-153. PubMed ID: 29271010
[TBL] [Abstract][Full Text] [Related]
16. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
Alachkar H; Mutonga M; Malnassy G; Park JH; Fulton N; Woods A; Meng L; Kline J; Raca G; Odenike O; Takamatsu N; Miyamoto T; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2015 Oct; 6(32):33410-25. PubMed ID: 26450903
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.
Qiu JJ; Lin YY; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
Gynecol Oncol; 2014 Jul; 134(1):121-8. PubMed ID: 24662839
[TBL] [Abstract][Full Text] [Related]
18. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Li Y; Yang Z; Li W; Xu S; Wang T; Wang T; Niu M; Zhang S; Jia L; Li S
Oncotarget; 2016 Feb; 7(6):6748-64. PubMed ID: 26745678
[TBL] [Abstract][Full Text] [Related]
19. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis.
Matsuo Y; Park JH; Miyamoto T; Yamamoto S; Hisada S; Alachkar H; Nakamura Y
Sci Transl Med; 2014 Oct; 6(259):259ra145. PubMed ID: 25338756
[TBL] [Abstract][Full Text] [Related]
20. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
